{
    "name": "fluocinolone",
    "comment": "Rx",
    "other_names": [
        "Synalar",
        "Capex",
        "Fluoderm",
        "DermaSmoothe FS"
    ],
    "classes": [
        "Corticosteroids",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/capex-derma-smooth-fs-fluocinolone-343518",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: excretion in milk unknown; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: excretion in milk unknown; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Chronic topical corticosteroid therapy may interfere with growth & development in pediatric patients",
                "Use med to very high potency for <2 wk to reduce local and systemic side effects ",
                "Use low potency for chronic therapy",
                "Kaposi's sarcoma reported with prolonged corticosteroid therapy; if noted, consider discontinuing therapy  ",
                "Avoid medium to very high potency on face, folds, groin because can increase steroid absorption",
                "Use lower potency for children (ie, increase BSA/kg, therefore increase systemic absorption)",
                "If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted",
                "Contact dermatitis may occur; may be diagnosed as failure to heal rather than clinical exacerbation",
                "As with any topical corticosteroid product, prolonged use may produce atrophy of skin and subcutaneous tissues; when used on intertriginous or flexor areas, or on face, this may occur even with short-term use",
                "In presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted; if a favorable response does not occur promptly, the corticosteroid should be discontinued until infection has been adequately controlled",
                "Avoid contact with the eyes",
                "Patients should be advised not to use this medication for any disorder other than that for which it was prescribed",
                "Shampoo only proven effective in corticosteroid-responsive dermatoses, other than seborrheic dermatitis of the scalp"
            ],
            "specific": [
                {
                    "type": "HPA axis suppression",
                    "description": [
                        "Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushingâ€™s syndrome, hyperglycemia, and glucosuria in some patients",
                        "Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings",
                        "Patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests",
                        "If HPA axis suppression is noted, an attempt should be made to withdraw drug, reduce frequency of application, or substitute a less potent steroid",
                        "Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug",
                        "Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids",
                        "Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Skin atrophy",
            "percent": "2"
        },
        {
            "name": "Striae",
            "percent": null
        },
        {
            "name": "Intracranial hypertension",
            "percent": null
        },
        {
            "name": "Telangiectasia",
            "percent": null
        },
        {
            "name": "Acneiform eruptions",
            "percent": null
        },
        {
            "name": "Ketatosis pilaris",
            "percent": null
        },
        {
            "name": "Papules",
            "percent": null
        },
        {
            "name": "Pustules",
            "percent": null
        },
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Dryness",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Pigmentation changes",
            "percent": null
        },
        {
            "name": "HPA suppression",
            "percent": null
        },
        {
            "name": "with higher potency used",
            "percent": null
        },
        {
            "name": "wk",
            "percent": null
        }
    ]
}